Stephen Liu

Stephen Liu is a thoracic oncologist focused on small cell lung cancer and thoracic malignancies with an emphasis on molecular biomarker identification and novel therapeutic development. He has contributed to trials of trilaciclib, tarlatamab, and other investigational SCLC agents and has analyzed molecular correlates of treatment response. His work spans clinical trial design, genomic profiling of SCLC, and patient advocacy to accelerate SCLC drug development. He is active in SCLC-focused professional working groups and has produced influential analyses of real-world outcomes in SCLC.